https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7958 Sat 24 Mar 2018 08:34:56 AEDT ]]> Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:995 Sat 24 Mar 2018 08:29:49 AEDT ]]>